Ginkgo Bioworks (DNA) News Today $6.36 -0.09 (-1.40%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Tao Capital Management LPTao Capital Management LP trimmed its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,683 shares of the company's stock after selling 221,671November 20 at 6:27 AM | marketbeat.comGinkgo Bioworks Holdings: Hold Rating Amidst Revenue Growth and Restructuring EffortsNovember 19 at 3:48 AM | markets.businessinsider.comUS Bancorp DE Decreases Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)US Bancorp DE decreased its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,336 shares of the company's stock aftNovember 19 at 3:09 AM | marketbeat.comGinkgo Bioworks: Unproven Transition But 2025 Is Looking BetterNovember 18 at 11:07 AM | seekingalpha.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short InterestGinkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 7,330,000 shares, a decline of 7.0% from the October 15th total of 7,880,000 shares. Currently, 20.7% of the company's shares are sold short. Based on an average daily trading volume, of 1,360,000 shares, the short-interest ratio is currently 5.4 days.November 18 at 7:40 AM | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by GSA Capital Partners LLPGSA Capital Partners LLP lessened its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 95.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 120,169 shares of the company's stock after sNovember 16, 2024 | marketbeat.comHead-To-Head Comparison: Novavax (NASDAQ:NVAX) vs. Ginkgo Bioworks (NYSE:DNA)November 16, 2024 | americanbankingnews.comGinkgo Bioworks price target lowered to $6 from $7 at BTIGNovember 15, 2024 | markets.businessinsider.comGinkgo Bioworks (NYSE:DNA) Shares Gap Up - Here's WhyNovember 15, 2024 | americanbankingnews.comPositive Outlook for Ginkgo Bioworks: Strategic Developments and Financial Strength Bolster Buy RatingNovember 14, 2024 | markets.businessinsider.comGinkgo Bioworks Reports Q3 Growth and Strategic DealsNovember 14, 2024 | markets.businessinsider.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comGinkgo Bioworks: Not Enough ProgressNovember 13, 2024 | seekingalpha.comBaillie Gifford & Co. Trims Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Baillie Gifford & Co. lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,358,581 shares of the company's stock after selling 131,067,285 shares during the periodNovember 13, 2024 | marketbeat.comGinkgo Bioworks Holdings Inc (DNA) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...November 13, 2024 | finance.yahoo.comGinkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comInsights into Ginkgo Bioworks Holdings's Upcoming EarningsNovember 12, 2024 | benzinga.comGinkgo Bioworks receives $9M milestone payment from Merck partnershipNovember 12, 2024 | markets.businessinsider.comGinkgo Bioworks Holdings, Inc. Q3 Loss DeclinesNovember 12, 2024 | markets.businessinsider.comGinkgo Bioworks Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | prnewswire.comGinkgo Bioworks Advances Collaboration with Merck to Improve Biologics ManufacturingNovember 12, 2024 | prnewswire.comTempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer CareNovember 11, 2024 | businesswire.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Receives Consensus Rating of "Reduce" from AnalystsNovember 11, 2024 | americanbankingnews.comGinkgo Bioworks (DNA) Set to Announce Quarterly Earnings on TuesdayGinkgo Bioworks (NYSE:DNA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Given Average Rating of "Reduce" by AnalystsGinkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) has been given a consensus recommendation of "Reduce" by the six ratings firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation anNovember 6, 2024 | marketbeat.comGinkgo Bioworks Announces Date of Third Quarter 2024 Results PresentationNovember 5, 2024 | prnewswire.comWith 48% ownership, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has piqued the interest of institutional investorsNovember 3, 2024 | finance.yahoo.comGinkgo Bioworks (DNA): A Leader in Cell Programming and Genetic DiagnosticsOctober 31, 2024 | msn.comGinkgo Bioworks Holdings, Inc. (DNA) Outpaces Stock Market Gains: What You Should KnowOctober 28, 2024 | msn.comForbes J M & Co. LLP Invests $1.02 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Forbes J M & Co. LLP purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 125,000 shares of the company's stock, valued at approximately $1,019,000. ForbeOctober 28, 2024 | marketbeat.comPFG Investments LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)PFG Investments LLC purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 189,030 shares of the company's stock, valueOctober 27, 2024 | marketbeat.comIn Climate Fight, Scientists Tinker With Bacteria to Replace Corn FertilizerOctober 24, 2024 | nytimes.comGinkgo Bioworks (NYSE:DNA) Trading Up 5% - Still a Buy?Ginkgo Bioworks (NYSE:DNA) Trading 5% Higher - Should You Buy?October 22, 2024 | marketbeat.comEquitec Proprietary Markets LLC Has $99,000 Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Equitec Proprietary Markets LLC cut its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 98.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,200 shares of the company's stock after selling 660,288 shares during the perioOctober 19, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Growth in Short InterestGinkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 8,190,000 shares, a growth of 29.0% from the September 15th total of 6,350,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is presently 5.5 days. Currently, 23.1% of the company's shares are short sold.October 15, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Trading 5.9% Higher - Still a Buy?Ginkgo Bioworks (NYSE:DNA) Stock Price Up 5.9% - Here's What HappenedOctober 15, 2024 | marketbeat.comExchange Traded Concepts LLC Has $2.99 Million Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Exchange Traded Concepts LLC trimmed its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 94.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 366,978 shares of the company's stockOctober 15, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Squarepoint Ops LLCSquarepoint Ops LLC lowered its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 47.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 349,591 shares of the company's stock after selling 313,794 shares during the perioOctober 14, 2024 | marketbeat.comAlgert Global LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Algert Global LLC acquired a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 107,785 shares of the company's stock, vaOctober 13, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Receives Average Recommendation of "Reduce" from AnalystsShares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) have been assigned an average rating of "Reduce" from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, two have issOctober 12, 2024 | marketbeat.comGinkgo Bioworks Holdings Inc (DNA) Q2 2024 Earnings Call Highlights: Strategic Restructuring ...October 9, 2024 | finance.yahoo.comGinkgo Bioworks (DNA) Shares Drop Amid Weak Earnings and Sell RatingsOctober 9, 2024 | gurufocus.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Stake Trimmed by Green Alpha Advisors LLCGreen Alpha Advisors LLC lessened its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 92.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,254 shares of the company's stock afterOctober 8, 2024 | marketbeat.comBoston Standard Wealth Management LLC Has $124,000 Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Boston Standard Wealth Management LLC cut its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,165 shares of the company's stock after sellOctober 7, 2024 | marketbeat.comVirica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy ManufacturingOctober 3, 2024 | businesswire.comRenaissance Technologies LLC Acquires New Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Renaissance Technologies LLC purchased a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 6,366,901 shares of the company's stock, valued at approximately $2,128,000. RenaissancOctober 3, 2024 | marketbeat.comRhumbline Advisers Sells 1,331,930 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Rhumbline Advisers lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 90.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 140,659 shares of the company's stock after selling 1,331,930 shares during theOctober 1, 2024 | marketbeat.com122,718 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Bought by Wellington Wealth Strategies LLC.Wellington Wealth Strategies LLC. acquired a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 122,718 shares of the company's stock, valued at apprSeptember 30, 2024 | marketbeat.comBenjamin F. Edwards & Company Inc. Raises Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Benjamin F. Edwards & Company Inc. grew its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 1,606.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2September 28, 2024 | marketbeat.comXTX Topco Ltd Purchases New Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)XTX Topco Ltd acquired a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 933,898 shares of the company's stock, valued at approximately $September 27, 2024 | marketbeat.com Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. DNA Media Mentions By Week DNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNA News Sentiment▼0.860.46▲Average Medical News Sentiment DNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNA Articles This Week▼136▲DNA Articles Average Week Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Spyre Therapeutics News Today Ocular Therapeutix News Today Day One Biopharmaceuticals News Today Travere Therapeutics News Today Praxis Precision Medicines News Today Cassava Sciences News Today Syndax Pharmaceuticals News Today ARS Pharmaceuticals News Today Arcus Biosciences News Today Kura Oncology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:DNA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNA Stock Alerts